Results 91 to 100 of about 423,879 (287)

A Natural Sweetener‐inducible Genetic Switch Controls Therapeutic Protein Expression in Mammals

Advanced Science, EarlyView.
This study develops a natural sweetener, the psicose‐inducible transgene expression (PURE) system based on an Agrobacterium tumefaciens–derived transcriptional repressor PsiR. The PURE system is highly specific to psicose, being insensitive to other sugars and structurally similar molecules.
Longliang Qiao, Zhihao Wang, Shasha Tang, Yuan Fang, Guiling Yu, Xiaoting Qiu, Lingxue Niu, Tao Yan, Xingwan Liu, Xiaoding Ma, Deqiang Kong, Yang Zhou, Ningzi Guan, Jinzhong Tian, Meiyan Wang, Haifeng Ye, Fengfeng Cai   +16 more
wiley   +1 more source

Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing

British Journal of Clinical Pharmacology
The aim of this study was to estimate adherence to urate‐lowering therapy (ULT), predominately allopurinol, from Australia's Pharmaceutical Benefits Scheme (PBS) claims database in association with (1) patient‐reported doses and (2) World Health ...
Marcel Schulz, M. Coleshill, R. Day, Daniel F. B. Wright, Jonathan Brett, Nancy E. Briggs, Eindra Aung   +6 more
semanticscholar   +1 more source

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study

Scientific Reports, 2022
Attribute-based medicine is essential for patient-centered medicine. To date, the groups of patients with chronic kidney disease (CKD) requiring urate-lowering therapy are clinically unknown.
H. Kataoka, T. Mochizuki, Mamiko Ohara, Yuki Tsuruta, Naomi Iwasa, Rie Yoshida, K. Tsuchiya, K. Nitta, K. Kimura, T. Hosoya, Kenjiro Tatsuo Sadayoshi Masaaki Yasuhiko Shunya Hirofumi Kimura Hosoya Ito Inaba Tomino Uchida Makino Matsu, S. Ito, M. Inaba, Y. Tomino, S. Uchida, H. Makino, S. Matsuo, H. Yamanaka, Tetsuya Yamamoto, I. Ohno, Y. Shibagaki, S. Iimuro, N. Imai, M. Kuwabara, H. Hayakawa, T. Akizawa, T. Teramoto, H. Kasanuki, K. Yoshimura, Hiroshi Sato, S. Horikoshi, S. Maruyama, Masahiko Inaba, Y. Moriwaki, H. Uchida, Nagayuki Kaneshiro, N. Imai, H. Moriya, Y. Komatsu, S. Kaname, Kazunari Hanaoka, M. Ogura, Masato Ikeda, K. Kasai, A. Sugiura, Kazushi Takahashi, K. Kojima, Hirofumi Tamai, Hiroshi Nagaya, S. Okuno, Ryusuke Kakiya, H. Takeoka, K. Hirata, K. Asano, Y. Fukaya, Yasushi Iwaida, Yasuo Tsuneda, S. Nishimura, T. Hiramatsu, Y. Isaka, Takafumi Ito, Y. Yuzawa, K. Yamagata, T. Sofue, Yoshimi Jinguji, K. Hirano, K. Matsuyama, T. Mizumoto, Yuko Shibuya, M. Sugawara, Moritoshi Kadomura, Yasuaki Teshima, H. Ohtani, H. Kamata, S. Okawara, M. Fukushima, K. Takemura, E. Kinugasa, M. Kogure, Yo Ehara   +79 more
semanticscholar   +1 more source

Prospects of anti-inflammatory and urate-lowering therapy of gout: A vector from the past to the future

Научно-практическая ревматология, 2022
The article provides an overview of new and promising drugs aimed at anti-inflammatory and urate-lowering therapy of gout, both already registered and used in clinical practice, and at the stages of implementation or clinical research and demonstrating ...
A. A. Garanin, N. L. Novichkova, N. L. Novichkova   +2 more
doaj   +1 more source

Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study [PDF]

, 2016
Objectives: To evaluate the persistence and adherence on urate-lowering treatment (ULT) in primary care 5 years after an initial nurse-led treatment of gout.
Abhishek Abhishek, Cottrell, Dalbeth, Gwen Fernandes, Hirsch, Jonathan La-Crette, Khanna, McGowan, Michael Doherty, Singh, Wendy Jenkins   +10 more
core   +2 more sources

Nanozymes for Energy and Environmental Sustainability

Advanced Science, EarlyView.
At present, the widely used nanozymes are oxidoreductase and hydrolase, which have proved to have great application prospects in energy and environment. ABSTRACT Nanozymes have shown remarkable promise in addressing pressing challenges in energy and environmental sustainability.
Xiaoqi Li, Jinxing Chen, Shaojun Dong
wiley   +1 more source

Adherence and Treat‐to‐Target Benchmarks in Older Adults With Gout Initiating Urate‐Lowering Therapy in Ontario, Canada: A Population‐Based Study

Arthritis care & research
We sought to evaluate urate‐lowering therapy (ULT) adherence and treatment‐to‐target (T2T) serum uric acid (SUA) levels among older adults with gout starting ULT.
Timothy S H Kwok, B. Kuriya, G. Hawker, L. Eder, Ping Li, G. Choy, J. Widdifield   +6 more
semanticscholar   +1 more source

Pregnancy and infection [letter] [PDF]

, 2014
Pregnant women have an increased severity of infections with some organisms, including influenza virus, hepatitis E virus, herpes simplex virus, and malaria parasites.
Athena P. Kourtis, Brabin BJ, Cardenas I, Denise J. Jamieson, Enders G, Gellin BG, Jennifer S. Read, McGregor IA, Medawar P, Smale LE, Smith JL, Vaughan JE   +11 more
core   +4 more sources

Clinical Relevance and Diagnostic Utility of Standard Serum Biomarkers in Advanced Chronic Kidney Disease: A Single‐Center Observational Study From Bangladesh

iLABMED, EarlyView.
This study evaluated conventional and emerging biochemical markers for assessing chronic kidney disease (CKD) progression in Bangladeshi patients elevated serum uric acid and parathyroid hormone levels, along with reduced eGFR, vitamin D, and albumin levels, were significantly associated with CKD, highlighting their potential as cost‐effective early ...
Fazlul Haque, Md. Samiul Islam, Nafsoon Rahman, Ayub Zawad, Sadia Afrin, Pulak Kanti Palit, Tanjil Hasan, Md. Isahak Ali, Shafin Ahmed, Akram Hossain, Marina Khatun, Tabassuma Marzia Prome, Md. Shah Alam, Ashekul Islam   +13 more
wiley   +1 more source

Perspective of Dutch Patients with Gout on Continuation or Discontinuation of Urate‐Lowering Therapy During Remission: A Mixed‐Methods Study

Arthritis care & research
Long‐term gout management is based on reducing serum urate by using urate‐lowering therapy (ULT). A lifelong treat‐to‐target approach is advocated, although a ULT (taper to) stop attempt can be considered (treat‐to‐avoid symptoms approach) during ...
I. R. Peeters, F. Veenstra, S. Wanten, Johanna E Vriezekolk, C. H. van den Ende, A. D. den Broeder, N. van Herwaarden, L. Verhoef, M. Flendrie   +8 more
semanticscholar   +1 more source